March 1, 2022 5:00pm
Wild swings in market as cell and gene therapy sector closes negative
The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works on Tuesday as 3,549 shares appear raising the share price +$0.59 to cut it before the close -$0.04 after Monday with 687 shares traded +$0.37 just before the close
Pre-open indications: Sell into Strength -11 Hits and profit with 1 Miss
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
March begins ...
Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?
If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed DOWN -582.36 points (-1.72%); the S&P closed DOWN -67.75 points (-1.55%) while the Nasdaq closed DOWN -218.94 points (-1.59%)
Henry’omics:
Indexes slipped on the first day of March as oil prices popped while the fighting between Russia and Ukraine continues and the U.S. does nothing but, talk a bad game.
This comes after yesterday’s (Monday) volatile session after the Dow lost 179 points or -0.53%, the S&P 500 dropped 10.87 points or -0.25% and the Nasdaq rose +56.78 points or +0.4%.
The good, the cell and gene therapy sector experienced a decline after three (3) upside sessions in a row – back to a non-happening February mode.
RegMed Investors’ (RMi) pre-open: “a volatile, earnings and headline driven sector and market” … https://www.regmedinvestors.com/articles/12321
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …
- Tuesday opened positive at 21 up/12 downs, 1 flat and 1 acquired, stayed positive at the mid-day at 19/15 and 1 acquired, ending with a negative close of 15/18, 1 flat and 1 acquired;
Pre-open Indications: 11 Hits < Biostage (OTCQB: BSTG -$0.04; Sell into Strength: < Alnylam Pharmaceuticals (ALNY +$4.66), Intellia Therapeutics (NTLA -$19.00), Ionis Pharmaceuticals (IONS +$0.70), Vericel (VCEL -$0.55), CRISPR Therapeutics (CRSP -$3.93), Global Blood Therapeutics (GBT -$0.33), ReNeuron (RENE.L -$1.00), MiMedx (MDXG -$0.03), Sage Therapeutics (SAGE +$0.24)> 1 Miss < BUY: AxoGen (AXGN -$0.28)>
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 … added (PGEN) and (RGNX) today
The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works on Tuesday as 3,271 shares appear raising the share price +$0.59 to have it close -$0.04 with an additional 278 shares traded after Monday with 687 shares traded +$0.37 just before the close after Friday closed flat with 70 shares traded and Thursday with the shares dumping -$0.67 on 1,259 shares traded
Key Metrics:
- Tuesday - Sector volume was LOW with 6 of the 15-upside having higher than the 3-month average volume with LOW volume of 4 of 18-downside having higher than the 3-month average volume
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Tuesday the IBB closed down -0.53% and XBI closed down -0.82%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Tuesday was up +3.17 points or +10.51% at 33.32
Jumping with share pricing momentum (10 of 15):
- Alnylam Pharmaceuticals (ALNY +$4.66),
- Ionis Pharmaceuticals (IONS +$0.70),
- uniQure NV (QURE +$0.49),
- Editas Medicine (EDIT +$0.37),
- Sage Therapeutics (SAGE +$0.24),
- Regenxbio (RGNX +$0.24),
- BioLife Solutions (BLFS +$0.21),
- Mesoblast (MESO +$0.16),
- Homology Medicine (FIXX =$0.06),
- Ultragenyx (RARE +$0.05),
Hammered in today’s market (10 of 18):
- Intellia Therapeutics (NTLA -$19.00),
- CRISPR Therapeutics (CRSP -$3.93),
- ReNeuron (RENE.L -$1.00),
- Vericel (VCEL -$0.42),
- bluebird bio (BLUE -$0.42),
- Global Blood Therapeutics (GBT -$0.33),
- AxoGen (AXGN -$0.28),
- Cellectis SA (CLLS -$0.20),
- Fate Therapeutics (FATE -$0.13),
- Bellicum Pharmaceuticals (BLCM -$0.12),
Closing:
1 – Verastem (VSTM) and 1 - Stemline Therapeutics (STML) – acquired
March, Q1/2022:
Tuesday closed negative with 15 incliners, 18 decliners, 1 flat and 1 acquired
The BOTTOM LINE: Markets ended sharply lower on Tuesday, with cell and gene therapy stocks feeling the pain after three (3) up sessions as the Russia-Ukraine crisis deepened and stirred agita among investors.
Gene editing investors are swimming in a soup of fear, after Intellia Therapeutics (NTLA -$19.00) and Crispr Therapeutics (CRSP -$3.90), post the U.S. patent office ruled the Broad Institute patent was “more” valid than UC Berkely. (Read more … https://www.regmedinvestors.com/articles/12320)
Although trading was so-so, the advance decline line spoke.
I thought that Monday’s war footing escalation would dominate a downside and it never happen to our sector – maybe I should be a better believer?
Remember the adage, “It takes two to make a market"; that’s sellers and buyers.
I am always anticipating the risks – as my careers focus has been “warning analysis”.
Q4 and end-of-year earnings are gaming than even I thought.
Earnings’ reporting coming:
· Athersys (ATHX), Tuesday, 3/15
· Cellectis SA (CLLS) Thursday, 3/22
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
